The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I): (Formula (I)) where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
-
Page/Page column 55
(2018/09/28)
GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
-
Paragraph 0337; 0338
(2018/12/11)
Proactive antitumor compounds
The present invention features proactive antitumor compounds of the following formula: wherein R1 is COOZ; Z being H, alkali metal, alkaline earth metal, an ammonium group which is optionally substituted with one or more alkyl groups, or a carboxyl protec
-
(2008/06/13)
More Articles about upstream products of 261511-11-9